Gesynta Pharma doses first patient in Phase II NOVA trial

​Gesynta Pharma has dosed the first patient in its Phase II trial, NOVA, investigating vipoglanstat, a non-hormonal, non-opioid drug for treating endometriosis.

The post Gesynta Pharma doses first patient in Phase II NOVA trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Viome PRO introduces blood test for pancreatic cancer
Alpheus begins multi-centre study for butterfly GBM
Biohaven partners with Ono in $100m IgG degrader deal
The pitfalls in hospitals’ ability to auction clinical labour
BD reports nine-month AGILITY trial data for Revello stent

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us